MGNX250117P17500
- 5.30
- 0.000.00%
Macrogenics Newsroom
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics Announces Leadership Transition in Financial Roles
Express News | Macrogenetics Dips in Volume Surge, Last Down 6.5%
JMP Securities Maintains Macrogenics(MGNX.US) With Hold Rating
MacroGenics Downgraded to Market Perform by JMP, Price Target Removed
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights
A Quick Look at Today's Ratings for Macrogenics(MGNX.US), With a Forecast Between $4 to $8
Express News | JMP Securities Downgrades Macrogenics to Market Perform
MacroGenics (MGNX) Was Downgraded to a Hold Rating at JMP Securities
Earnings Call: MacroGenics Reports a Revenue Jump to $110.7 Million
MacroGenics' Transition Phase: Balancing Potential and Uncertainty Amid Leadership and Pipeline Developments
MacroGenics' Strategic Moves and Promising Pipeline Justify Buy Rating
MacroGenics Margenza Rights Sale a Positive, Says Leerink
Q3 2024 MacroGenics Inc Earnings Call
Macrogenics Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Express News | MacroGenics Inc : BMO Raises Target Price to $6 From $5
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
Balanced Hold Rating Reflects Cautious Optimism and Strategic Risks for MacroGenics
Barclays Maintains Macrogenics(MGNX.US) With Buy Rating, Maintains Target Price $8